Journal article icon

Journal article

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.

Abstract:

BACKGROUND: Calcineurin inhibitors (CNIs) reduce short-term kidney transplant failure, but might contribute to transplant failure in the long-term. The role of alemtuzumab (a potent lymphocyte-depleting antibody) as an induction treatment followed by an early reduction in CNI and mycophenolate exposure and steroid avoidance, after kidney transplantation is uncertain. We aimed to assess the efficacy and safety of alemtuzumab-based induction treatment compared with basiliximab-based induction t...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Trial Service Unit
Role:
Author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Trial Service Unit, BHF Centre of Research Excellence
Role:
Author
Expand authors...
Journal:
Lancet
Volume:
384
Issue:
9955
Pages:
1684-1690
Publication date:
2014-11-05
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
URN:
uuid:1165f73f-5f05-44d2-892e-320482910331
Source identifiers:
482581
Local pid:
pubs:482581
Language:
English
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP